Gamma Variant RBD-based ARVAC-CG vaccine
/ National University of San Martin, National Scientific and Technical Research Council, Pablo Cassara
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
December 22, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P2/3 | N=2014 | Completed | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 22, 2023
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P1 | N=80 | Completed | Sponsor: Laboratorio Pablo Cassara S.R.L. | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP
September 28, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P2/3 | N=2014 | Active, not recruiting | Sponsor: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
October 04, 2023
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P1 | N=80 | Active, not recruiting | Sponsor: Laboratorio Pablo Cassara S.R.L. | Trial completion date: Jun 2023 ➔ Oct 2023
Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IFNG
March 02, 2023
ARVAC-F2/3-002: ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19)
(clinicaltrials.gov)
- P2/3 | N=2014 | Recruiting | Sponsor: Mónica Edith Lombardo
New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
December 19, 2022
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
(clinicaltrials.gov)
- P1 | N=80 | Active, not recruiting | Sponsor: Laboratorio Pablo Cassara S.R.L.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IFNG
July 12, 2022
COVID-19 vaccination certificates and lifting public health and social measures: ethical considerations.
(PubMed, East Mediterr Health J)
- "Vaccination certificates may undermine a population-based approach to COVID-19 vaccination to achieve and accelerate universal lifting of PHSMs, result in unfair and inequitable health and social outcomes, and generate social divisions at a time when solidarity within (and between) countries is necessary to navigate the pandemic and its burdens. Further research on the ethical acceptability and impact of COVID-19 vaccine certificates in countries that have implemented them should be carried out to inform future ethical considerations on this issue."
Journal • Infectious Disease • Novel Coronavirus Disease
1 to 7
Of
7
Go to page
1